

SAFETY DATA SHEET

1. Identification

Product identifier Olmesartan Medoxomil

Other means of identification

Catalog number 1478367

Chemical name 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)

[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester

Recommended use Specified quality tests and assay use only.

Recommended restrictions Not for use as a drug. Not for administration to humans or animals.

Manufacturer/Importer/Supplier/Distributor information

Company name U. S. Pharmacopeia
Address 12601 Twinbrook Parkway

Rockville MD

20852-1790

US

Telephone RS Technical Services 301-816-8129

www.usp.org

E-mail RSTECH@usp.org

Emergency phone number CHEMTREC within US & 1-800-424-9300

Canada

CHEMTREC outside US & +1 703-527-3887

Canada

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Reproductive toxicity Category 1

OSHA hazard(s) Not classified.

Label elements

Website



Signal word Danger

Hazard statement May damage fertility or the unborn child.

Precautionary statement

Prevention Obtain special instructions before use. Do not handle until all safety precautions have been read

and understood. Wear protective gloves/protective clothing/eye protection/face protection.

Response If exposed or concerned: Get medical advice/attention.

Storage Store locked up.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Hazard(s) not otherwise

classified (HNOC)

Not classified.

3. Composition/information on ingredients

Substance

Hazardous components

Chemical nameCommon name and synonymsCAS number%Olmesartan Medoxomil144689-63-4100

4. First-aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Material name: Olmesartan Medoxomil

Ingestion

Most important symptoms/effects, acute and

Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately. Cardiovascular effects.

sympton delayed

Indication of immediate medical attention and special treatment needed

Treatment of angiotensin II antagonist overdose should be symptomatic and supportive and may include the following: Administer activated charcoal as a slurry. Consider gastric lavage if it can be performed soon after ingestion. For hypotension, infuse isotonic fluid. If hypotension persists, administer dopamine or norepinephrine. Hemodialysis may not be effective in removal. (Meditext)

General information

Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting measures

Suitable extinguishing media

Use fire-extinguishing media appropriate for surrounding materials. Water. Foam. Dry chemical or

CO2.

Unsuitable extinguishing

media

None known.

Specific hazards arising from the chemical

No unusual fire or explosion hazards noted.

Special protective equipment and precautions for firefighters

Wear suitable protective equipment.

Fire-fighting

equipment/instructions
Specific methods

Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Clean surface thoroughly to remove residual contamination.

7. Handling and storage

Precautions for safe handling

As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly.

Conditions for safe storage, including any incompatibilities

Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure controls/personal protection

Biological limit values Exposure guidelines No biological exposure limits noted for the ingredient(s).

No exposure standards allocated.

Appropriate engineering controls

Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Local exhaust ventilation such as a laboratory fume hood or other vented enclosure is recommended, particularly for grinding, crushing, weighing, or other dust-generating procedures.

Individual protection measures, such as personal protective equipment

Eye/face protection

Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.

Skin protection

Hand protection

Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex

gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.

Other For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.

Material name: Olmesartan Medoxomil

USP SDS US

Respiratory protection Where respirators are deemed necessary to reduce or control occupational exposures, use

NIOSH-approved respiratory protection and have an effective respirator program in place

(applicable U.S. regulation OSHA 29 CFR 1910.134).

Thermal hazards Not available.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

9. Physical and chemical properties

Appearance White to light yellowish-white powder or crystalline powder.

Physical stateSolid.FormPowder.

Odor Odorless or slight characteristic odor.

Odor threshold Not available.

pH Not available.

Melting point/freezing point 351.7 °F (177.6 °C)

Initial boiling point and boiling

range

Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Not available.

Solubility in water Practically insoluble.

Partition coefficient

(n-octanol/water)

Not available.

Auto-ignition temperature815 °F (435 °C)Decomposition temperatureNot available.ViscosityNot available.

Other information

Chemical familyImidazole.Molecular formulaC29H30N6O6Molecular weight558.59

Solubility (other) Sparingly soluble in methanol and in acetone; slightly soluble in acetonitrile and in anhydrous

ethanol; practically insoluble in diethyl ether.

10. Stability and reactivity

Reactivity No reactivity hazards known.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid None known.

Incompatible materials None known.

Hazardous decomposition

products

NOx. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

11. Toxicological information

Information on likely routes of exposure

Ingestion Based on available data, the classification criteria are not met.

Inhalation Due to lack of data the classification is not possible.

Material name: Olmesartan Medoxomil

7490 Version #: 02 Revision date: 03-13-2014 Issue date: 12-28-2011

Skin contact Due to lack of data the classification is not possible.

Eve contact Due to lack of data the classification is not possible.

Symptoms related to the physical, chemical, and toxicological characteristics

Angiotensin II antagonists: Nausea. Vomiting. Diarrhea. Indigestion. Headache. Dizziness. Fatigue. Fainting. Bone pain. Muscle pain. Angiodema. Fast heartbeat. Slow breathing.

Delayed and immediate effects

of exposure

Angiotensin II antagonists: Hypotension. Arrhythmia. Kidney failure. Hypokalemia.

Medical conditions aggravated

by exposure
Acute toxicity

Angiotensin II antagonists: Heart failure. Kidney impairment.

Based on available data, the classification criteria are not met.

Product Species Test Results

Olmesartan Medoxomil (CAS 144689-63-4)

Oral

LD50

Mouse > 2000 mg/kg
Rat > 2000 mg/kg

Skin corrosion/irritation

Due to lack of data the classification is not possible.

Serious eye damage/eye

Due to lack of data the classification is not possible.

irritation

Respiratory sensitizationDue to lack of data the classification is not possible.

Skin sensitization Based on available data, the classification criteria are not met.

Sensitization

Antigenicity tests Result: Negative. Species: Guinea pig Antigenicity tests Result: Negative. Species: Mouse

Germ cell mutagenicity Due to lack of data the classification is not possible. Data from germ cell mutagenicity tests were

not found.

Mutagenicity

Ames assay Result: Negative.

Chromosomal aberrations in cultured cells in vitro

Result: Positive.

In vitro Syrian hamster embryo cell transformation

assay

Result: Negative.

Mouse bone marrow micronucleus test in vivo

Result: Negative.

MutaMouse intestine and kidney in vivo

Result: Negative.

Thymidine kinase mutations in in vitro mouse lymphoma

assay

Result: Positive.

Carcinogenicity Based on available data, the classification criteria are not met. This material is not considered to

be a carcinogen by IARC, NTP, or OSHA.

1000 mg/kg/day Carcinogenicity study Result: No evidence of carcinogenic effects.

Species: Mouse

Test Duration: 6 months

2000 mg/kg/day Carcinogenicity study

Result: Not carcinogenic.

Species: Rat

Test Duration: 2 years

Reproductive toxicity May damage fertility or the unborn child. Therapeutic use of drugs that act on the

renin-angiotensin system during the second and third trimesters of pregnancy has been

associated with fetal and newborn injury and death.

Reproductivity

1 mg/kg/day Reproductivity study

Result: No malformations.

Species: Rabbit

1000 mg/kg/day Reproductivity study Result: No increase in congenital anomalies.

Species: Rat

Material name: Olmesartan Medoxomil

USP SDS US

Specific target organ toxicity -

single exposure

Due to lack of data the classification is not possible.

repeated exposure

Due to lack of data the classification is not possible.

Specific target organ toxicity -

Based on available data, the classification criteria are not met. **Aspiration hazard**

12. Ecological information

Ecotoxicity

Product Test Results Species

Olmesartan Medoxomil (CAS 144689-63-4)

Fish LC50 Fish > 10 mg/l

Persistence and degradability No data is available on the degradability of this product.

Bioaccumulative potential Not available. Mobility in soil Not available. Other adverse effects Not available.

13. Disposal considerations

Disposal instructions Dispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the

user of the product to determine, at the time of disposal, whether the product meets RCRA criteria

for hazardous waste.

Local disposal regulations Not available. Hazardous waste code Not available.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

Not regulated as a hazardous material by DOT.

IATA

Not regulated as a dangerous good.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

No information available.

15. Regulatory information

US federal regulations CERCLA/SARA Hazardous Substances - Not applicable.

One or more components are not listed on TSCA.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance Nο

SARA 311/312 Hazardous

No

chemical

Other federal regulations

Safe Drinking Water Act

(SDWA)

Not regulated.

Food and Drug

Administration (FDA)

Not regulated.

US state regulations California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material

is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

Material name: Olmesartan Medoxomil

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	Yes
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other information, including date of preparation or last revision

 Issue date
 12-28-2011

 Revision date
 03-13-2014

Version # 02

Further information Not available.

Disclaimer USP Reference Standards are sold for chemical test and assay purposes only, and NOT for

human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY

AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information

contained herein.

Revision Information This document has undergone significant changes and should be reviewed in its entirety.

Material name: Olmesartan Medoxomil usp sos us